236 related articles for article (PubMed ID: 27184779)
1. Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.
Montgomery RA; Orandi BJ; Racusen L; Jackson AM; Garonzik-Wang JM; Shah T; Woodle ES; Sommerer C; Fitts D; Rockich K; Zhang P; Uknis ME
Am J Transplant; 2016 Dec; 16(12):3468-3478. PubMed ID: 27184779
[TBL] [Abstract][Full Text] [Related]
2. C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.
Viglietti D; Gosset C; Loupy A; Deville L; Verine J; Zeevi A; Glotz D; Lefaucheur C
Am J Transplant; 2016 May; 16(5):1596-603. PubMed ID: 26693703
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
Jordan SC; Choi J; Aubert O; Haas M; Loupy A; Huang E; Peng A; Kim I; Louie S; Ammerman N; Najjar R; Puliyanda D; Vo A
Am J Transplant; 2018 Dec; 18(12):2955-2964. PubMed ID: 29637714
[TBL] [Abstract][Full Text] [Related]
6. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
[TBL] [Abstract][Full Text] [Related]
8. Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients.
Huang E; Vo A; Choi J; Ammerman N; Lim K; Sethi S; Kim I; Kumar S; Najjar R; Peng A; Jordan SC
Clin J Am Soc Nephrol; 2020 Jan; 15(1):109-116. PubMed ID: 31843975
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
10. Complement-Based Therapy in the Management of Antibody-Mediated Rejection.
Bhalla A; Alachkar N; Alasfar S
Adv Chronic Kidney Dis; 2020 Mar; 27(2):138-148. PubMed ID: 32553246
[TBL] [Abstract][Full Text] [Related]
11. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
[TBL] [Abstract][Full Text] [Related]
12. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.
Kulkarni S; Kirkiles-Smith NC; Deng YH; Formica RN; Moeckel G; Broecker V; Bow L; Tomlin R; Pober JS
Am J Transplant; 2017 Mar; 17(3):682-691. PubMed ID: 27501352
[TBL] [Abstract][Full Text] [Related]
15. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated rejection implies a poor prognosis in kidney transplantation: Results from a single center.
Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Ruiz P; Vianna R; Burke GW
Clin Transplant; 2018 Oct; 32(10):e13392. PubMed ID: 30152116
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
[TBL] [Abstract][Full Text] [Related]
20. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
